Study guide
16.3 Half-Life & Basic Kinetic Calculations
APC Intern Written Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals
2 Legal Framework: PBS & Medicine Schedules
2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)
3 Legal Framework: Privacy, National Law & Pharmacy Board
3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards
4 Patient-Centred Medication Management
4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management
5 Primary Care & Judicious Use of Medicines
5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices
6 Dispensing & Clinical Appropriateness
6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes
7 Counselling & Acute Care
7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response
8 Therapeutics: Cardiovascular & Endocrine
8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders
9 Therapeutics: Infection, Respiratory & Gastrointestinal
9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health
10 Therapeutics: Neurology, Psychiatry & Pain
10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics
11 Therapeutics: Special Populations & Systems
11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment
12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology
12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management
13 Monitoring: Clinical Review
13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications
14 Monitoring: Safety & Adverse Drug Reactions
14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring
15 Compounding Medicines
15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations
16 Pharmaceutical Calculations
16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations
17 Promote Health & Well-Being
17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency
16.3 Half-Life & Basic Kinetic Calculations
Key Takeaways Explain This Topic AI
Elimination half-life (t½) is the time for plasma concentration (or amount in the body) to fall by 50% during the terminal elimination phase.
After about four half-lives roughly 6.25% remains (~94% eliminated); five half-lives leave about 3%—useful rules for washout questions.
Steady state on regular dosing is approached by about four to five half-lives of the dosing regimen for linear kinetics.
Loading dose and steady-state concentration concepts link dose, volume of distribution, clearance, and dosing rate without requiring advanced multi-compartment maths.
Renal impairment can prolong half-life for renally cleared drugs, often needing longer intervals or lower maintenance doses—interpret qualitatively for exam scenarios.
Last updated: August 2026
15.3 Half-Life & Basic Kinetic Calculations
Quick Answer: Elimination half-life (t½) is the time for drug concentration to drop by half . Use it to estimate how long to wash out , when steady state is near , and how renal impairment may stretch dosing intervals. Intern Written kinetics stay at conceptual formulas and clean arithmetic —not full multi-compartment modelling. FIB items may ask for remaining concentration, number of half-lives, or hours to a stated fraction remaining; enter the exact number the stem’s units require.
Kinetics link compounding numeracy (Standard 3.4 ) to monitoring sense (Standard 3.3 ): knowing when levels matter is as important as how to calculate a volume.
What half-life means
For first-order elimination (the usual exam assumption for these rules of thumb):
- After 1 × t½ : 50% remains
- After 2 × t½ : 25% remains
- After 3 × t½ : 12.5% remains
- After 4 × t½ : 6.25% remains → about 94% eliminated
- After 5 × t½ : 3.125% remains → about 97% eliminated
Half-life is a time (hours, days). It is not a concentration and not a dose.
Worked example A — remaining fraction
A drug has t½ = 6 hours . Starting concentration 80 mg/L (assume no further doses, distribution complete).
- Time Half-lives elapsed Concentration
- 0 h 0 80 mg/L
- 6 h 1 40 mg/L
- 12 h 2 20 mg/L
- 18 h 3 10 mg/L
- 24 h 4 5 mg/L
After 12 hours (2 half-lives): 20 mg/L remains.
FIB practice: if asked “concentration after 12 h in mg/L,” enter 20 .
Worked example B — time to ~94% elimination
t½ = 8 hours . Time for ~4 half-lives ≈ 4 × 8 = 32 hours .
If the stem asks how many hours until roughly 6% remains, answer 32 (hours).
Worked example C — how many half-lives?
Concentration falls from 64 mg/L to 4 mg/L .
64 → 32 → 16 → 8 → 4 = 4 half-lives
If t½ = 3 h, time elapsed = 12 h.
Steady state (~4–5 half-lives)
On repeated fixed dosing with linear kinetics, plasma levels rise until input equals elimination . Steady state (Css) is effectively approached after about 4–5 elimination half-lives of continuous or regular therapy—not after 4–5 doses unless the dosing interval equals the half-life.
Worked example D — time to steady state
Drug t½ = 12 hours , given regularly every 12 hours.
4 × t½ = 48 h; 5 × t½ = 60 h → expect near steady state in about 2–2.5 days
If t½ = 6 hours :
4–5 half-lives ≈ 24–30 hours
Exam interpretation: measuring a level after one dose of a long half-life drug does not represent steady-state Css. Timing of levels (trough versus peak) still matters clinically; half-life only tells the accumulation timeline .
Basic Css and loading-dose concepts (no advanced PK required)
You should recognise relationships, not derive multi-compartment AUCs.
Maintenance rate and clearance
At steady state, roughly: Dosing rate ≈ C L × C s s \text{Dosing rate} \approx CL \times C_{ss} Dosing rate ≈ C L × C ss
So if clearance falls (for example severe renal impairment for a renally cleared drug), the same dosing rate produces a higher Css —maintenance doses often need reduction or intervals lengthened.
Loading dose concept
A loading dose fills the volume of distribution to a target concentration quickly: L D ≈ C t a r g e t × V d LD \approx C_{target} \times V_d L D ≈ C t a r g e t × V d
- (Bioavailability F may appear as LD ≈ (Ctarget × Vd) / F for oral products.)
- Worked example E — loading dose arithmetic
Target concentration 10 mg/L , Vd 30 L , IV (F = 1).
LD = 10 × 30 = 300 mg
FIB: 300 (mg).
Worked example F — why load?
If t½ is 24 hours , waiting for steady state on maintenance alone may take 4–5 days . A loading dose reaches therapeutic levels early , while maintenance keeps Css. Exam stems test the idea more than obscure constants.
Dosing interval intuition
Drugs with short t½ may need more frequent dosing (or formulations that slow input) to avoid large peak–trough swings.
Drugs with long t½ can often be given less frequently once loaded, but take longer to clear after stopping and longer to reach Css.
Renal impairment and half-life (qualitative + simple numbers)
If a drug is largely renally cleared , falling eGFR can reduce clearance , prolong t½ , and raise accumulation risk at unchanged doses.
Worked example G — qualitative
A renally cleared drug has t½ 4 hours in normal function. In severe impairment, t½ might lengthen substantially (exact factor is drug-specific—use AMH-style guidance in practice). Exam reasoning:
- Longer t½ → longer time to steady state if started without a load
- Longer t½ → higher troughs if the interval is not adjusted
- Stopping the drug → slower washout (more half-lives of calendar time)
- Worked example H — washout comparison
Normal t½ 4 h → ~4 half-lives ≈ 16 h to ~94% gone.
If t½ becomes 12 h → ~4 half-lives ≈ 48 h to the same residual fraction.
You do not invent a new half-life number without data; you interpret direction when the stem states impairment and a renally cleared agent.
Linking kinetics to dosing-interval questions
Typical Intern Written patterns:
When can I re-challenge / when is most drug gone? → count ~4 half-lives for ~94% elimination (unless the stem defines another threshold).
When are steady-state levels meaningful? → after ~4–5 half-lives on a stable regimen (and correct sample timing).
Why reduce dose in renal failure? → lower CL → higher Css if rate unchanged; t½ may rise.
Loading versus maintenance → load uses Vd × target; maintenance matches elimination (CL × Css).
Worked example I — multi-step half-life
Peak (post-distribution) level 32 mg/L , t½ 5 hours . What is the level after 15 hours if no further drug is given?
- 15 h = 3 half-lives
- 32 → 16 → 8 → 4 mg/L
- Worked example J — percent eliminated
After 2 half-lives , fraction remaining = 25%, so fraction eliminated = 75% .
After 4 half-lives , remaining 6.25%, eliminated 93.75% ≈ 94% .
FIB technique for kinetic numbers
Decide whether the blank wants concentration , hours , number of half-lives , or dose (mg) .
Halve concentrations once per half-life —do not divide by the half-life value itself (a common error: “t½ = 6 h so divide concentration by 6”).
Time elapsed ÷ t½ = number of half-lives only when units match (both hours).
Keep linear first-order assumptions unless the stem signals saturation kinetics.
Round only as the stem requires; many pure halving sequences stay exact (80 → 40 → 20).
Putting Standard 3.4 calculations together
Chapters 14–15 form the compounding and calculation band of the blueprint (~8% combined weight with formulation). In practice and on exam day:
- Section 16.1 turns a prescribed dose into mg and mL and day supply
- Section 16.2 turns labelled strengths into recipes and safe dilutions
- Section 16.3 turns half-life into timing and accumulation literacy
Use scrap paper, SI units, and magnitude checks on every FIB. Exact arithmetic under time pressure is a registrable pharmacist skill—not optional numeracy.